Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Assets (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Current Assets for 16 consecutive years, with $332.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 11.61% to $332.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $332.6 million, a 11.61% increase, with the full-year FY2025 number at $332.6 million, up 11.61% from a year prior.
  • Current Assets was $332.6 million for Q4 2025 at Myriad Genetics, down from $344.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $538.9 million in Q2 2021 to a low of $261.6 million in Q1 2023.
  • A 5-year average of $341.5 million and a median of $305.8 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 62.47% in 2021, then crashed 43.36% in 2022.
  • Myriad Genetics' Current Assets stood at $484.8 million in 2021, then plummeted by 43.36% to $274.6 million in 2022, then increased by 14.2% to $313.6 million in 2023, then fell by 4.97% to $298.0 million in 2024, then grew by 11.61% to $332.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Current Assets are $332.6 million (Q4 2025), $344.8 million (Q3 2025), and $284.3 million (Q2 2025).